Login to Your Account



Array boosts data ahead of NDA for BRAF/MEK combo in melanoma

By Jennifer Boggs
Managing Editor

Wednesday, May 10, 2017

While last year's positive readout from the first part of Array Biopharma Inc.'s phase III COLUMBUS trial testing binimetinib and encorafenib in BRAF-mutant advanced, unresectable or metastatic melanoma cleared the way for regulatory filings, supplementary results from the study's second part could bolster the combination's prospects.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription